EUCTR2019-002477-56-GB进行中（未招募）1 期
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia - Immunogen IMGN632-0802
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 274
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patient must be = 18 years of age.
- •2. Patients must have confirmed diagnosis of AML (excluding acute promyelocytic leukemia) based on World Health Organization classification.
- •3. Disease characteristics and allowable prior therapy:
- •a. Patients must be evaluated for any available standard of care therapies (including induction, consolidation chemotherapy and/or transplant) and, in the opinion of the treating physician, be deemed appropriate for this experimental therapy.
- •b. Treatment-naïve (untreated) patients will be allowed in the Expansion Phase for Regimens A (IMGN632 + azacitidine) and C (Triplet) (IMGN632 + azacitidine + venetoclax) in separate cohorts. No prior treatments with hypomethylating agents (HMAs) for MDS are allowed.
- •Note: Patients who are MRD+ following frontline treatment are eligible for the Regimen D Cohorts D1 and D2 (Expansion Phase).
- •c. Patients must have CD123-positive AML as confirmed by local flow cytometry (or immunohistochemistry [IHC]).
- •d. Patients may have received prior CD123-targeted therapies, except IMGN632, as long as CD123 remains detectable during screening.
- •e. Relapsed or refractory CD123-positive AML patients will be allowed to enroll in the Escalation Phase of Regimens A, B, and C (Triplet)
- •(IMGN632 + azacitidine, venetoclax, or azacitidine + venetoclax, respectively) and relapsed CD123-positive AML patients will be allowed to enroll the Expansion Phase of Regimens A-C.
- •Note: Patients may also have received up to 2 prior lines of therapy, eg, frontline treatment (induction, consolidation [including transplant], and maintenance) and 1 salvage regimen.
- •f. Patients enrolling in Regimen D must be in CR (CR/CRh/CRp/CRi) for no more than 6 months and be MRD+ at the time of screening, confirmed
- •by central laboratory testing, after induction/consolidation therapy (which may include stem cell transplant).
- •Note: Fit patients who previously received intensive treatment (eg 3+7, HiDAC, etc.) are eligible for Regimen D Cohort D1. Unfit patients who previously received nonintensive treatment (eg, HMA, low dose cytarabine, etc.) are eligible for Regimen D Cohort D2.
- •4. Eastern Cooperative Oncology Group performance status = 1. If nonambulatory due to a chronic disability, must be Karnofsky
- •performance status > 70.
- •5. Previous treatment-related toxicities must have resolved to Grade 1 or baseline (excluding alopecia).
- •6. Total white blood cell count must be less than 25 × 10e9 cells/L. Hydroxyurea may be used to control blood counts before Cycle 1 Day 1, at the discretion of the treating physician, according to institutional practice. During the Escalation Phase in Regimens A-C, hydroxyurea may also be used during Cycle 1.
- •7. Liver enzymes (AST and ALT) = 3 × the upper limit of normal (ULN).
- •8. Total bilirubin = 1.5 × the ULN within 14 days of enrollment.
- •9. Serum creatinine = 1.5 mg/dL within 14 days of enrollment.
- •10. Left ventricular ejection fraction (LVEF) = 45% based on locally available assessment, eg, ECHO or other modality.
- •11. Patients with prior autologous and allogeneic bone marrow transplant are eligible. Patients with an allogeneic transplant must meet
- •the following conditions: The transplant must have been performed more than 120 days before the date of dosing on this study, the patient must
- •not have active = Grade 2 graft versus host disease, and the patient must be off potent systemic immunosuppression for at least 2 weeks
- •before dosing.
- •12. Voluntary written informed consent before performan
排除标准
- •1. Patients who have received any anticancer therapy, including investigational agents, within 14 days (or within 28 days for checkpoint inhibitors) before drug administration on this study (hydroxyurea is allowed before beginning study treatment). Patients must have recovered to baseline from all acute toxicity from this prior therapy.
- •2. Patients who have been previously treated with IMGN632.
- •3. Patients with myeloproliferative neoplasm–related secondary AML are excluded from the Dose Expansion Phase of the study.
- •4. Patients with active central nervous system (CNS) AML will be excluded. A lumbar puncture does not need to be performed unless there
- •is clinical suspicion of CNS involvement per investigator judgement. Concurrent therapy for CNS prophylaxis or continuation of therapy for
- •controlled CNS AML is allowed with the approval of the sponsor.
- •5. Patients with a history of sinusoidal obstruction syndrome/venous occlusive disease of the liver.
- •6. Myocardial infarction within 6 months before enrollment or New York Heart Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities before study entry.
- •7. Clinically relevant active infection including known active hepatitis B or C, HIV infection, or cytomegalovirus or any other known concurrent infectious disease that, in the judgment of the investigator, would make a patient inappropriate for enrollment into this study (testing not required).
- •8. Patients who have undergone a major surgery within 4 weeks (or longer if not fully recovered) before study enrollment.
- •9. Serious or poorly controlled medical conditions that could be exacerbated by treatment or that would seriously compromise safety assessment or compliance with the protocol, in the judgment of the investigator.
- •10. Women who are pregnant or breastfeeding.
- •11. Prior known hypersensitivity reactions to monoclonal antibodies (=Grade 3).
- •12. Prior known hypersensitivity reactions to study drugs and/or any of their excipients.
研究者
相似试验
进行中（未招募）
1 期
A study of IMGN632 alone or in combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid LeukemiaCD123 positive Acute Myeloid LeukemiaMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002477-56-ITIMMUNOGEN, INC.274
进行中（未招募）
1 期
A study of IMGN632 alone or in combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid LeukemiaCD123 positive Acute Myeloid LeukemiaMedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002477-56-ESImmunoGen, Inc.212
进行中（未招募）
1 期
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT04086264AbbVie218
进行中（未招募）
1 期
A Phase 2 Study of IMAB362 as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 ExpressioMetastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaMedDRA version: 20.0Level: LLTClassification code 10066354Term: Adenocarcinoma of the gastroesophageal junctionSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10071114Term: Metastatic gastric adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10001150Term: Adenocarcinoma gastricSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-002566-50-FRAstellas Pharma Global Development, Inc. (APGD)102
招募中
不适用
A Phase I/II Study of Combination Therapy of CG200745 PPA (Histone Deacetylase Inhibitor) with Gemcitabine and Erlotinib to Determine the Maximum Tolerated Dose and Evaluate the Safety and Efficacy for Locally Advanced Unresectable, or Metastatic Pancreatic CancerNeoplasmsKCT0002037CrystalGenomics48